Acceleron Pharma (XLRN) Misses Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Misses Q3 EPS by 2c

Acceleron Pharma Reports Third Quarter 2016 Financial and Operational Results

November 3, 2016 4:06 PM EDT

- Appointed Habib Dable as President and CEO effective December 1, 2016 -

- Five upcoming presentations at American Society of Hematology Annual Meeting in December -

- Advancing ACE-083 into Phase 2 study for facioscapulohumeral muscular dystrophy (FSHD) -

- Maintained strong balance sheet with $251 million in cash to fund projected operating requirements into the second half of 2019 -

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and... More